Results
CLL14ILUMINATE
Venetoclax+obinotuzumab vs clorambucil+obinotuzumab Ibrutinib+obinotuzumab vs clorambucilo+obinotuzumab
No of patients 432 1:1 229 1:1
Age (years) (median) 72 70
High risk (Binet/Rai) (%) 43 52
Patient with del p17 (%) 8 14
Patients with tp53 (%) 9.5 15.5
Unmutated IGHV (%) 60 757
Indirect comparison
PFS HR 0.66 (95% CI 0.36 to 1.22, p=0.18) ibrutinib favoured
PFS at 24 months RR 0.64 (95% CI 0.32 to 1.08, p=0.09) ibrutinib favoured
MRD peripheral blood RR 1.41 (95% CI 0.85 to 2.32, p=0.18) venetoclax favoured
CR RR 0.85 (95% CI 0.39 to 1.86, p=0.69) venetoclax favoured
Cost
Venetoclax+obinotuzumab Ibrutinib+obinotuzumab
12 months (€) 76 374 76 786
24 months (€) 76 374 127 891